Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Level 2?
Data Shows That the Global Addiction Treatment Market is Set to Grow
9:00 AM ET 3/23/18 | Dow Jones
FinancialBuzz.com News Commentary
NEW YORK, March 23, 2018 /PRNewswire/ --
Data provided by Transparency Market Research, indicates that global addiction treatment market was valued at approximately US$ 4.0 billion in 2016 and is anticipated to expand at a CAGR of over 6.0% from 2017 to 2025 or reaching value of approximately US$ 7.0 billion by 2025. Drug abuse and addiction treatments are provided in several different settings by using a number of behavioral and pharmacological approaches. The report indicates that in terms of treatment type, tobacco and nicotine addiction treatment segment is projected to dominate the market and is expected to continue this trend during the forecast period followed by the opioid addiction treatment segment. BioCorRx Inc. (OTC: BICX), Egalet Corporation (NASDAQ: EGLT), Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), BioDelivery Sciences International, Inc. (NASDAQ: BDSI), DURECT Corporation (NASDAQ: DRRX)
According to BCC Research, the opioid abuse segment is projected to be valued at $2.5 billion by 2021. Addiction to opioids is on the rise and is leading to serious health problems. The New York Times reported data provided by the CDC, according to which Drug overdoses killed roughly 64,000 people in the United States in 2016. A very strong increase of more than 22 percent from the previous year. According to the Times, "Drug overdoses are expected to remain the leading cause of death for Americans under 50, as synthetic opioids - primarily fentanyl and its analogues - continue to push the death count higher."
BioCorRx Inc. (OTCQB: BICX) earlier this week commented, "on President Trump's initiative to stop opioid abuse and address factors fueling the opioid crisis, including over-prescription, illicit drug supplies, and insufficient access to evidence-based treatment, primary prevention, and recovery support services. The White House issued a fact sheet on March 19, 2018 addressing the driving forces of the opioid crisis. According to the fact sheet, one of the initiatives "will help those struggling with addiction through evidence-based treatment and recovery support services." Medication-assisted treatment (MAT) is evidence-based and one of the medications used in MAT is naltrexone. The fact sheet specifically discusses naltrexone use in the criminal justice system for offenders struggling with substance use disorder."
Brady Granier, CEO of BioCorRx, Inc., stated, "We appreciate President Trump's proactive stand in addressing the opioid epidemic. We have been an early leader in the field of MAT therapy specific to naltrexone for opioid use disorder (OUD) and expect these new initiatives will help spur wider adoption of MAT. We strongly believe the most effective treatment for OUD is the combination of medication with cognitive behavioral therapy (CBT) and peer support, which has proven highly effective for those patients treated with our BioCorRx(R) Recovery Program. Our program was recently adopted in Philadelphia in collaboration with One Day at a Time (ODAAT), a program funded by the city of Philadelphia and state of Pennsylvania. As previously announced, we have already met with the FDA and received positive feedback on BICX102, our sustained release naltrexone implant. The FDA deemed the project acceptable for a 505(b)(2) pathway, which we believe will be a more abbreviated and cost-effective route to approval. We have received strong support from the National Institute on Drug Abuse (NIDA) and we are currently finalizing our application for a NIDA grant. We look forward to the implementation of the President's initiatives, which we believe will have a meaningful impact on combating the opioid crisis."
Egalet Corporation (NASDAQ: EGLT), a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. In February, the company announced that one of the largest Northeast regional health plans has placed ARYMO ER (morphine sulfate) extended-release (ER) tablets for oral use only -CII and SPRIX (ketorolac tromethamine) Nasal Spray in preferred formulary positions, effective immediately. "Obtaining preferred coverage of both ARYMO ER and SPRIX Nasal Spray is important to ensure access to our products for healthcare providers and for the individuals covered by this large health plan," said Patrick Shea, chief commercial officer of Egalet. "With the ongoing opioid epidemic, we believe that improved access to non-narcotic and abuse-deterrent treatment options is critical to try and decrease prescription opioid abuse in our communities."
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is a specialty pharmaceuticals company that develops therapeutics for select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform, ProNeura. The company's lead product is Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction. The U.S. Food and Drug Administration approved Probuphine on May 26, 2016. Probuphine is the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single administration procedure. Recently, the company announced that it has entered into a definitive asset purchase, supply and support agreement with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. through which Molteni has acquired the European intellectual property related to Probuphine, including the Marketing Authorization Application (MAA) under review by the European Medicines Agency (EMA), and will have the exclusive right to commercialize the Titan supplied Probuphine product in Europe, as well as certain countries of the Commonwealth of Independent States, the Middle East and North Africa
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain and opioid dependence. In February, the company announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. (Teva) that resolves BDSI's previously reported BELBUCA(R) (buprenorphine) buccal film (CIII), patent litigation against Teva pending in the United States District Court for the District of Delaware. BDSI alleged in the lawsuits that the generic form of BELBUCA which Teva is seeking approval to market in the United States pursuant to three Abbreviated New Drug Application (ANDA) filings with the U.S. Food and Drug Administration (FDA), infringed upon two U.S. patents owned by BDSI.
DURECT Corporation (NASDAQ: DRRX) is a biopharmaceutical company developing therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms. DURECT has now staked out important positions in areas as diverse as pain management, psychiatry, metabolic disease, and acute organ injury. DURECT's advanced oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late stage product candidate in this category is POSIMIR(SABER(R)-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to 3 days of continuous pain relief after surgery. In February, the company announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with primary sclerosing cholangitis (PSC). DUR-928, the lead investigational product in our Epigenetic Regulator Program, is an endogenous, first-in-class small molecule, which may have broad applicability in several hepatic and renal diseases such as nonalcoholic steatohepatitis (NASH) and other disorders of the liver such as PSC, in acute organ injuries such as acute liver and kidney injury, and in inflammatory skin disorders such as psoriasis and atopic dermatitis.
13K @ 0.146 at opening .. highest PPS in 2 weeks
Hey guys . I have a feeling of a little break out to the 0.16 range today . You agree !!?
Level 2 ? Anyone ?
300k BUYS so far in the day !
( BICX ) SeeThruEquity Issues Update on BioCorRx Inc. (OTCQB: BICX) and Increases Price Target to $0.44
Font size: A | A | A
9:25 AM ET 3/20/18 | Dow Jones
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on BioCorRx Inc.
(OTCQB: BICX).
The report is available here: BICX March 2018 Update Note.
Based in Anaheim, CA, BioCorRx, Inc. (OTCQB: BICX, "BioCorRx") develops and provides advanced solutions for the treatment of alcohol and opioid use disorders. The company's BioCorRx(R) Recovery Program is a non-addictive, medication-assisted treatment (MAT) program, which consists of two main components: 1) an outpatient implant procedure using naltrexone in a sustained release form, which can significantly reduce physical cravings for alcohol and opioids; and 2) a proprietary cognitive behavioral therapy (CBT) program and overlapping peer recovery support specifically tailored for those receiving long-term naltrexone treatment. BioCorRx is also developing injectable and other implantable naltrexone products for potential future regulatory approval through its subsidiary BioCorRx Pharmaceuticals. We see the company as offering high risk and high growth potential as it targets the multi-billion dollar market for addiction treatment.
Highlights from the note include:
BioCorRx differentiated by two-pronged approach to treatment
We are updating our overage of BioCorRx following recent developments at the company since we initiated coverage. BioCorRx is pursuing a two-pronged approach to the treatment of substance abuse addiction, including the BioCorRx(R) Recovery Program, and BioCorRx Pharmaceuticals, a subsidiary advancing a drug development program for the company's formulation and delivery method for naltrexone through candidates BICX101 and BICX102. The company's treatment program is thought to address many of the shortcomings of the current standard of care, including the combination of therapy and medication, as well as the utilization of non-addictive medication to suppress addiction. Naltrexone is a non-addictive opioid receptor antagonist that works in the brain's reward system, thereby blocking some of the effects of alcohol and drugs.
Encouraging pre-IND meetings with FDA
Positive pre-IND meeting with FDA for BICX102. On February 12, 2018, BioCorRx announced that it had completed a positive pre-Investigational New Drug (IND) meeting with the FDA for BICX102, which is the company's sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. According to the release, the FDA deemed the 505(b)(2) pathway as an acceptable route for approval of BICX102 for both alcohol and opioid indications in its pre-Investigational New Drug (IND) meeting. Assuming access to external funding, the 505(b)(2) route should enable a relatively faster and more cost-effective path to market for BICX102, as BioCorRx should not be required to perform additional efficacy studies given the existing body of information on the implant that they already possess coupled with the data which exists in the public domain on naltrexone in other forms. Rather, BioCorRx plans to perform a nonclinical safety study, a clinical pharmacokinetic (PK) study and clinical safety and human factor testing. We see this as a significant development for the company, as it will open access to the large and expanding market for drugs to treat addiction, potentially positioning BICX102 as an alternative to injectable naltrexone from Alkermes plc.
Updating price target to $0.44 for BICX
We are updating our price target to $0.44 for BioCorRx. The company has several potential catalysts ahead as it seeks to gain approval for BICX102 and BICX101 while looking to expand its BioCorRx(R) Recovery Program and weight loss program currently being piloted.
Please review important disclosures at www.seethruequity.com.
About BioCorRx Inc.
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
BioCorRx Comments on President Donald J. Trumps Initiative to Stop Opioid Abuse
10:40 AM ET 3/20/18 | GlobeNewswire
BioCorRx Comments on President Donald J. Trump's Initiative to Stop Opioid Abuse
ANAHEIM, CA, March 20, 2018 (GLOBE NEWSWIRE) --
BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today commented on President Trump's initiative to stop opioid abuse and address factors fueling the opioid crisis, including over-prescription, illicit drug supplies, and insufficient access to evidence-based treatment, primary prevention, and recovery support services. The White House issued a fact sheet on March 19, 2018 addressing the driving forces of the opioid crisis. According to the fact sheet, one of the initiatives "will help those struggling with addiction through evidence-based treatment and recovery support services." Medication-assisted treatment (MAT) is evidence-based and one of the medications used in MAT is naltrexone. The fact sheet specifically discusses naltrexone use in the criminal justice system for offenders struggling with substance use disorder.
Brady Granier, CEO of BioCorRx, Inc., stated, "We appreciate President Trump's proactive stand in addressing the opioid epidemic. We have been an early leader in the field of MAT therapy specific to naltrexone for opioid use disorder (OUD) and expect these new initiatives will help spur wider adoption of MAT. We strongly believe the most effective treatment for OUD is the combination of medication with cognitive behavioral therapy (CBT) and peer support, which has proven highly effective for those patients treated with our BioCorRx(R) Recovery Program. Our program was recently adopted in Philadelphia in collaboration with One Day at a Time (ODAAT), a program funded by the city of Philadelphia and state of Pennsylvania. As previously announced, we have already met with the FDA and received positive feedback on BICX102, our sustained release naltrexone implant. The FDA deemed the project acceptable for a 505(b)(2) pathway, which we believe will be a more abbreviated and cost-effective route to approval. We have received strong support from the National Institute on Drug Abuse (NIDA) and we are currently finalizing our application for a NIDA grant. We look forward to the implementation of the President's initiatives, which we believe will have a meaningful impact on combating the opioid crisis."
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
I know that part lol .. was just messing with you .... happy to see a little bit of interest starting to arise again :)
Means ......???
Developments in the Obesity Treatment Market
9:25 AM ET 3/16/18 | Dow Jones
NEW YORK, March 16, 2018 /PRNewswire/ --
According to Grand View Research, the global obesity treatment market was valued at USD 3.9 billion in 2015 and is expected to reach $15.6 billion by 2024. The demand for weight management continues to increase as obesity posts an enormous challenge to healthcare in developed countries as well as in lower and middle-income economies. According to the Institute of Health Metrics and Evaluation, about 30% of the global population is either obese or overweight. In addition, increasing awareness of obesity's impacts on health further drives the growth of the market. The report indicated that the North American region holds the largest market share of global obesity treatment market due to growing overweight and obese population. BioCorRx Inc. (OTC: BICX), Zafgen,Inc. (NASDAQ: ZFGN), ReShape Lifesciences Inc. (NASDAQ: RSLS), VIVUS, Inc. (NASDAQ: VVUS), ReShape Lifesciences Inc. (NASDAQ: RSLS), Obalon Therapeutics, Inc. (NASDAQ: OBLN)
According to another report from Marketdata, the commercial weight loss programs segment of the obesity market is estimated to have grown 9.4 percent to $3.03 billion in 2017. John LaRosa, the Research Director of Marketdata, said: "The number of active dieters is estimated to have fallen 10% since 2015, to 97 million, due to a growing size acceptance movement and dieter fatigue. About 80% try to lose weight by themselves, but many fail and the latest CDC statistics show that we are getting fatter, not thinner. The new 2018 diet season is about to begin in late December, and the giants of the market are strongly positioned for more gains."
BioCorRx Inc. (OTCQB: BICX) yesterday announced, "an update on the pilot program for weight loss with Atlantis Medical Wellness & Weight Loss Center. The weight loss program began in October 2017 and the Company reports that Atlantis has successfully enrolled a total of twelve individuals to date as planned into the program. The initial results have been positive as reported by patients.
As mentioned in the Company's previous release, BioCorRx has teamed up with Dr. Benjamin Gonzalez, Medical Director of Atlantis Medical Wellness & Weight Loss Center in Silver Spring, MD. Dr. Gonzalez is renowned for his expertise in clinical nutrition with a focus on exercise nutrition and weight management.
According to the CDC, more than one-third (36.5%) of U.S. adults have obesity. According to a 2012 article in the Journal of Health Economics, estimates of current healthcare costs of obesity range from $147 billion to nearly $210 billion per year. Some of the risks associated with this disease include heart disease and stroke, high blood pressure, metabolic syndrome, breathing problems and other health issues."
Brady Granier, CEO, President, and Director of BioCorRx, stated, "We are very pleased with the feedback we have received from Dr. Gonzalez and the patients enrolled in the pilot program to date. We anticipated that this program would help individuals struggling with their weight in some way, but it's great to actually hear the excitement from those enrolled thus far. One of the first patients who enrolled in the program reported a weight loss of 25 pounds after three months along with healthier lifestyle habits. So far, most of the participants polled have expressed reduced cravings for food. We look forward to completing the pilot mid-year and plan to begin marketing the official weight loss program as anticipated immediately thereafter."
Zafgen,Inc. (NASDAQ: ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. In 2018, Zafgen plans to file an investigational new drug (IND) application with the U.S. FDA and initiate Phase 1 clinical trials for ZGN-1258, its new molecule for the treatment of Prader-Willi syndrome and potential other rare and serious forms of obesity. On January 5, 2018, the company announced strong clinical progress with its lead ZGN-1061 program currently in development for patients with complex type 2 diabetes. Additionally, the company unveiled plans to return to the rare metabolic disease space in 2018, with a second highly optimized MetAP2 development candidate, ZGN-1258, targeting an initial indication in Prader-Willi syndrome. ZGN-1258 is designed to change the way the body metabolizes fat, reduce fat mass and decrease hyperphagia in PWS, a rare genetic form of life-threatening obesity characterized by unrelenting pathologic hunger (hyperphagia) leading to dangerous food-seeking behavior.
ReShape Lifesciences Inc. (NASDAQ: RSLS) is a medical device company focused on technologies to treat obesity and metabolic diseases. Recently, the company announced an exclusive federal government business channel sales agreement with Academy Medical, LLC to sell its ReShape Balloon(TM) and ReShape vBloc(TM) products to U.S. Department of Defense (DoD) medical facilities. Through this agreement, the ReShape Balloon and ReShape vBloc are both now approved products for sale into DoD medical facilities. This new agreement adds increased distribution by Academy Medical of ReShape vBloc, which has been distributed through Academy Medical to VA facilities since May 2016. Academy Medical is a certified Service-Disabled Veteran-Owned Small Business specializing in the distribution of medical products to VA and DoD hospitals and community-based outpatient clinics.
VIVUS, Inc. (NASDAQ: VVUS) is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. The company's products are indicated for the treatment of obese and overweight patients and for erectile dysfunction. Erectile dysfunction can lead to reduced quality of life for the millions of men living with the condition. Recently, the company reported financial results for the quarter and year ended December 31, 2017 and provided a business update. Total revenue, net for the fourth quarters of 2017 and 2016, was $11.9 million and $81.8 million, respectively. Approximately 91,000 and 100,000 Qsymia prescriptions were dispensed in the fourth quarters of 2017 and 2016, respectively. Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.
Obalon Therapeutics, Inc. (NASDAQ: OBLN) is a San Diego-based, vertically integrated medical technology company focused on developing and commercializing novel technologies for weight loss. Obalon has launched the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity. On March 05, 2018, the company announced its audited financial results as of and for the fourth quarter and full year ended December 31, 2017. The Company reported total revenue of $3.7 million for the fourth quarter of 2017, compared to $0.8 million for the fourth quarter of 2016. U.S. revenue of $2.9 million represented 78% of total revenue and international revenue of $0.8 million represented 22% of total revenue for the fourth quarter 2017.
BioCorRx Provides Update on New Weight Management Program
8:08 AM ET 3/15/18 | GlobeNewswire
BioCorRx Provides Update on New Weight Management Program
ANAHEIM, CA, March 15, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced an update on the pilot program for weight loss with Atlantis Medical Wellness & Weight Loss Center. The weight loss program began in October 2017 and the Company reports that Atlantis has successfully enrolled a total of twelve individuals to date as planned into the program. The initial results have been positive as reported by patients.
As mentioned in the Company's previous release, BioCorRx has teamed up with Dr. Benjamin Gonzalez, Medical Director of Atlantis Medical Wellness & Weight Loss Center in Silver Spring, MD. Dr. Gonzalez is renowned for his expertise in clinical nutrition with a focus on exercise nutrition and weight management.
According to the CDC, more than one-third (36.5%) of U.S. adults have obesity. According to a 2012 article in the Journal of Health Economics, estimates of current healthcare costs of obesity range from $147 billion to nearly $210 billion per year. Some of the risks associated with this disease include heart disease and stroke, high blood pressure, metabolic syndrome, breathing problems and other health issues.
Brady Granier, CEO, President, and Director of BioCorRx, stated, "We are very pleased with the feedback we have received from Dr. Gonzalez and the patients enrolled in the pilot program to date. We anticipated that this program would help individuals struggling with their weight in some way, but it's great to actually hear the excitement from those enrolled thus far. One of the first patients who enrolled in the program reported a weight loss of 25 pounds after three months along with healthier lifestyle habits. So far, most of the participants polled have expressed reduced cravings for food. We look forward to completing the pilot mid-year and plan to begin marketing the official weight loss program as anticipated immediately thereafter.
Revenue forecast : near term 2020/2021 is bet. $88 million to $245 million with market penetration of 1% for BICX
Listening to the webcast as I am texting now !!!
90% buys so far
Very strong feeling that the conference call scheduled today at 2:00 pm eastern time will have a POSITIVE effect on the PPS before close today !! Finger crossed :)
So guys !!! What is the deal now ? We buying more ? Selling ? How long that pause and freeze situation staying ? I am just confused how to proceed ? Any thoughts ?
Current Report Filing (8-k)
Source: Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 28, 2018
BioCorRx Inc.
(Exact name of registrant as specified in its charter)
Nevada
000-54208
90-0967447
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employee
Identification No.)
2390 East Orangewood Avenue, Suite 575
Anaheim, California 92806
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (714) 462-4880
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure
Effective February 28, 2018, senior management and certain members of the Board of Directors of BioCorRx Inc. (the “Company”) have begun using the materials included in Exhibit 99.1 to this report (the “Investor Presentation”) in connection with presentations to existing shareholders of the Company, potential investors of the Company, and the investment community. The Investor Presentation provides an overview of the Company’s strategy, performance and future objectives. The Investor Presentation is incorporated into this Item 7.01 by reference and will be available on the Company’s website at www.biocorrx.com.
Without limiting the generality of the foregoing, the “Forward-Looking Statements” disclosure contained in the Investor Presentation is incorporated by reference into this Item 7.01. The information contained in this Item 7.01 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and such information is not incorporated by reference into any registration statements or other document filed under the Securities Act of 1933, as amended or the Exchange Act, regardless of the general incorporation language contained in such filing, except as shall be expressly set forth by specific reference to this filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
BioCorRx Inc. Investor Presentation (February 2018)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIOCORRX INC.
Date: March 1, 2018
By:
/s/ Lourdes Felix
Lourdes Felix
Chief Financial Officer
3
8k out
Pip email
BOTH !! company timing + panic response from traders
Been trading stocks for 8 years, made money & lost money but NEVER NEVER NEVER seen such STUPIDTY !!!!!!
1 million shares traded with 32% drop in price in 11 minutes of trading !! woooow
I guess will have to Absorb the early trading hit :(
BID 0.144 ASK 0.145
READ CAREFULLY , FROM YESTERDAY's FILING
THE REVERSE SPLIT
General
The Board is recommending that our stockholders approve granting the Board discretionary authority within the next twelve (12) months to file a Certificate of Amendment to the Articles to effectuate the Reverse Split (the “Reverse Split Amendment”) of all of our issued and outstanding shares of common stock at an exchange ratio of not less than 1-for-5 and not more than 1-for-500, which we sometimes refer to as the Reverse Split. The form of the Reverse Split Amendment is attached to this Information Statement as Appendix B.
If this proposal is approved, the Board will have the authority, but not the obligation, in its sole discretion and without any further action on the part of the stockholders, to effect the Reverse Split within this range at any time it believes to be most advantageous to our Company and stockholders. The exact ratio of the Reverse Split, if effected, would be set at a whole number within the range as determined by the Board in its sole discretion. The Reverse Split Amendment would not change the number of authorized shares of our common stock and the par value of our common stock would remain at $0.001 per share. As of the date of this Information Statement, we do not have any current plans, arrangements or understandings related the issuance of any additional shares of common stock that will become newly available as a result of the Reverse Split.
By potentially increasing our stock price, the Reverse Stock Split would potentially increase our minimum bid or share price required for the initial listing requirements for The Nasdaq Capital Market (“Nasdaq”). We currently do not meet the Nasdaq listing requirements, including the minimum bid price and shareholders’ equity. The Reverse Stock Split will not cause us to meet all of the listing requirements for Nasdaq. However, we believe the Reverse Stock Split will increase our stock price which may help us move towards eventually meeting the minimum share price requirements. We can provide no assurances that the Reverse Stock Split will have a long-term positive effect on the market price of our common stock, or increase our ability to be listed or approved for trading on Nasdaq.
We believe that enabling our Board to set the ratio within the stated range will provide us with the flexibility to implement the Reverse Split in a manner designed to maximize the anticipated benefits for our stockholders. In determining a ratio, if any, following the receipt of stockholder approval, our Board of Directors may consider, among other things, factors such as:
* the initial listing requirements of Nasdaq;
* the historical trading price and trading volume of our common stock;
* the number of outstanding shares of our common stock;
* the then-prevailing trading price and trading volume of our common stock and the anticipated impact of the Reverse Split on the trading market for our common stock; and
* prevailing general market and economic conditions.
Depending on the ratio for the Reverse Split determined by our Board of Directors, no less than 5 and no more than 500 shares of existing issued and outstanding common stock, as determined by our Board of Directors or a committee thereof, will be combined into one share of common stock. The Reverse Split Amendment, if any, will effect only the Reverse Split Ratio within such range determined by our Board to be in the best interests of our stockholders.
The Board will retain the authority not to effect the Reverse Split even if we receive stockholder approval. Thus, subject to stockholder approval, the Board, at its discretion, may cause the filing of the Reverse Split Amendment to effect a Reverse Split or abandon it and effect no Reverse Split if it determines that such action is not in the best interests of our Company and stockholders.
Purpose of the Reverse Split
The Board is submitting the proposed Reverse Split to our stockholders for approval in connection with the plan to apply to list our common stock on Nasdaq. The Board believes the consummation of the Reverse Split and the listing of our common stock on Nasdaq will make our common stock more attractive to a broader range of institutional and other investors. Accordingly, for these and other reasons described in this Information Statement, we believe that effecting the Reverse Split is in the Company’s and our stockholders’ best interests.
We believe that the Reverse Split will enhance our ability to obtain an initial listing on Nasdaq. Nasdaq requires, among other items, an initial bid price of least $4.00 per share and following initial listing, maintenance of a continued price of at least $1.00 per share. A decrease in the number of outstanding shares of our common stock resulting from a Reverse Split should, absent other factors, increase the per share market price of our common stock, although we cannot provide any assurance that our minimum bid price would remain over the minimum bid price requirement of Nasdaq following the Reverse Split.
Additionally, we believe that the Reverse Split will make our common stock more attractive to a broader range of institutional and other investors, as we have been advised that the current market price of our common stock may affect its acceptability to certain institutional investors, professional investors and other members of the investing public. As previously discussed, many brokerage houses and institutional investors have internal policies and practices that either prohibit them from investing in low-priced stocks or tend to discourage individual brokers from recommending low-priced stocks to their customers. In addition, some of those policies and practices may function to make the processing of trades in low-priced stocks economically unattractive to brokers. Moreover, because brokers’ commissions on low-priced stocks generally represent a higher percentage of the stock price than commissions on higher-priced stocks, the current average price per share of common stock can result in individual stockholders paying transaction costs representing a higher percentage of their total share value than would be the case if the share price were substantially higher. We believe that the Reverse Split will make our common stock a more attractive and cost effective investment for many investors, which will enhance the liquidity of the holders of our common stock.
Reducing the number of outstanding shares of our common stock through the Reverse Split is intended, absent other factors, to increase the per share market price of our common stock in order to attract new investors and meet one of the initial listing requirements of Nasdaq. However, other factors, such as our financial results, market conditions and the market perception of our business may adversely affect the market price of our common stock. As a result, we cannot assure you that the Reverse Split, if completed, will result in the intended benefits described above, that the market price of our common stock will increase following the Reverse Split or that the market price of our common stock will not decrease in the future. Additionally, we cannot assure you that the market price per share of our common stock after a Reverse Split will increase in proportion to the reduction in the number of shares of our common stock outstanding before the Reverse Split. Accordingly, the total market capitalization of our common stock after the Reverse Split may be lower than the total market capitalization before the Reverse Split.
Procedure for Implementing the Reverse Split
The Reverse Split, if approved by our stockholders, would become effective upon the filing (the “Effective Time”) of the Reverse Split Amendment with the Office of the Secretary of State of the State of Nevada. The Reverse Split Amendment will implement the exchange ratio (of not less than 1-for-5 nor more than 1-for-500) as determined by the Board of Directors prior to the Effective Time. The exact timing of the filing of Reverse Split Amendment will be determined by our Board of Directors based on its evaluation as to when such action will be the most advantageous to the Company and our stockholders. In addition, our Board of Directors reserves the right, notwithstanding stockholder approval and without further action by the stockholders, to elect not to proceed with the Reverse Split if, at any time prior to filing the Reverse Split Amendment, our Board, in its sole discretion, determines that it is no longer in our best interest and the best interests of our stockholders to proceed with the Reverse Split.
Effect of the Reverse Split on Holders of Outstanding Common Stock
The Reverse Split will not affect any stockholder's percentage ownership interest in our Company, except as described below in "Fractional Shares." Record holders of our common stock otherwise entitled to a fractional share as a result of the Reverse Split because they hold a number of shares not evenly divisible by the Reverse Split Ratio will automatically be entitled to receive an additional fraction of a share of our common stock to round up to the next whole share. In addition, the Reverse Split will not affect any stockholder's proportionate voting power (subject to the treatment of fractional shares as discussed herein).
The Reverse Split will not change the terms of our common stock. After the Reverse Split, the shares of our common stock will have the same voting rights and rights to dividends and distributions and will be identical in all other respects to our common stock now authorized. Our common stock will remain fully paid and non-assessable.
After the effective time of the Reverse Split, we will continue to be subject to the periodic reporting and other requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reverse Split is not intended as, and will not have the effect of, a "going private transaction" as described by Rule 13e-3 under the Exchange Act.
If we fail to meet the requirements specified in Nasdaq’s listing standards, our common stock will continue to be quoted on the OTCQB under the symbol "BICX."
After the effective time of a Reverse Split, the post-split market price of our common stock may be less than the pre-split price multiplied by the Reverse Split Ratio. In addition, a reduction in number of shares of our common stock outstanding may impair the liquidity for our common stock, which may reduce the value of our common stock.
The availability of a substantial number of authorized but un-issued shares of our common stock resulting from the Reverse Split, under various scenarios, may be construed as having an anti-takeover effect by permitting the issuance of shares of our common stock to purchasers who might oppose a hostile takeover bid or oppose any efforts to amend or repeal certain provisions in our Articles of Incorporation or bylaws as then in effect. The proposal to effectuate the Reverse Split did not result from our knowledge of any specific effort to accumulate our securities or to obtain control of us by means of a merger, tender offer, proxy solicitation in opposition to management or otherwise, and our Board did not authorize the Reverse Split to increase the authorized shares of our common stock to enable us to frustrate any efforts by another party to acquire a controlling interest or to seek representation on our Board.
In addition, the Reverse Split will increase the number of stockholders of the Company who own odd lots (less than 100 shares). Stockholders who hold odd lots typically will experience an increase in the cost of selling their shares, as well as possible greater difficulty in effecting such sales. Consequently, there can be no assurance that the Reverse Split will achieve the desired results that have been outlined above.
After reading all posts since yesterday ( Good & Bad ) ... IMO , the PPS will keep rising up steadily .. we have a great company with great product .. the R/S is for a very good reason .
Pip check your email
I think one happened @0.17
Bought me some more BICX Shares yesterday (even though I Don't need any more) just couldn't resist :) ...
Another BUY order in place this morning ... ITS TIME TO BUY !!!
All one block !!
under BID selling is back .... !!! 50K at 0.15 just went through
The Story Behind Growth: New Report Discusses Biocorrx and Repro-Med Emerging Trends Within New Industry
Published:Monday, February 26th 2018, 8:37 am EST
Updated:Monday, February 26th 2018, 8:37 am EST
NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Biocorrx, Inc. (OTCQB: BICX) and Repro-Med Systems, Inc. (OTCQX: REPR), including recent technical analysis and consolidated fundamental information.
Growth Market Report Initiates Coverage on:
BICX DOWNLOAD: http://GrowthMarketReport.com/signup/?co=BICX
REPR DOWNLOAD: http://GrowthMarketReport.com/signup/?co=REPR
Biocorrx Inc. (BICX) REPORT OVERVIEW
On February 23rd, 2018, Biocorrx, Inc. closed out the trading session at $0.13 (up 13.42%), compared to the previous day close of $0.12. The volume on the day was 747,637 (down 35.45%), compared to the company’s previous day volume of 1,158,224. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Biocorrx reported revenue of $0.70MM vs $0.92MM (down 24.11%). Biocorrx is expected to report earnings on April 12th, 2018, the report will be for the fiscal period ending December 31st, 2017.
Access Growth Market Report’s Biocorrx, Inc. Research Report at:
http://GrowthMarketReport.com/signup/?co=BICX
Repro-Med Systems Inc. (REPR) REPORT OVERVIEW
On February 23rd, 2018, Repro-Med Systems, Inc. closed out the trading session at $1.32 (down 2.22%), compared to the previous day close of $1.35. The volume on the day was 34,320 (down 13.58%), compared to the company’s previous day volume of 39,715. For the twelve months ended February 28th, 2017 vs February 29th, 2016, Repro-Med reported revenue of $12.29MM vs $12.25MM (up 0.38%) and basic earnings per share -$0.01 vs $0.02.
Access Growth Market Report’s Repro-Med Systems, Inc. Research Report at:
http://GrowthMarketReport.com/signup/?co=REPR
Our Actionable Research on Biocorrx Inc. (OTCQB: BICX) and Repro-Med Systems Inc. (OTCQX: REPR) can be downloaded free of charge at
http://GrowthMarketReport.com.
ABOUT Growth Market Report
It’s no secret that Wall Street analysts spend the lion’s share of their time focused on large, well-known companies and securities – they make most of their money from investment banking. As a result, small cap companies are relatively underserved when it comes to top-quality research and analysis. Growth Market Report was developed to fill in that gap.
happened earlier in the day ,around 10am , but again who knows !!
see it !!! just happened
BID was 0.1175 / ASK was 0.12 and a 50K trade popped out on the screen at 0.115
selling under BID ...
THE UNDER BID SELLER IS STARTING REAL EARLY TODAY LOL
He can't even wait till lunch time ..
it's gona be UGLY ...
They will take it down below 0.10 before quit selling under BID
Same bulk trading just happened at 0.125
Already Rich parker !!! loading more as it goes lower .. good luck ...